Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 4/20 | 0.35 |
| ▸ | OPRK1 | P41145 | 4/20 | 0.35 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.35 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | SPPL2A | Q8TCT8 | 3/20 | 0.31 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31676061 | 0.78 | KMT2A (0.36) | CHRM2ADRA2AALDH1A1KMT2AHTR2A | |
| SCHEMBL31676362 | 0.72 | SPPL2A (0.41) | CHRM2ADRA2AOPRM1OPRK1OPRL1 | |
| SCHEMBL25409744 | 0.67 | CYP1A2 (0.39) | OPRM1OPRK1OPRL1KMT2A | |
| SCHEMBL25410229 | 0.65 | ANPEP (0.44) | HTR2ASPPL2A | |
| SCHEMBL25408832 | 0.65 | ANPEP (0.44) | HTR2ASPPL2A | |
| SCHEMBL14358172 | 0.63 | CHRM2 (0.47) | CHRM2ADRA2AKDM1AALDH1A1KMT2A | |
| SCHEMBL10924920 | 0.63 | KDM1A (0.53) | CHRM2KDM1AALDH1A1KMT2AMEN1 | |
| SCHEMBL25408472 | 0.60 | KMT2A (0.44) | ALDH1A1KMT2AMEN1SPPL2A | |
| SCHEMBL30617078 | 0.60 | KMT2A (0.44) | ALDH1A1KMT2AMEN1SPPL2A | |
| SCHEMBL25436458 | 0.58 | SPPL2A (0.40) | OPRM1OPRK1OPRL1ALDH1A1SPPL2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263416-A1 | SPPL2a INHIBITORS | INCYTE CORPORATION | 2025-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250263416-A1 | SPPL2a INHIBITORS | SPPL2A, SPPL2B, BACE1 | CHRM2 4092/4885ADRA2A 1720/4885OPRM1 4708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.